Cynata Therapeutics Ltd

Commences Treatment in Second Patient Cohort in Cynata’s World First Clinical Trial:Cynata Therapeutics Ltd (ASX: CYP) has treated the first patient in Cohort B with CYP-001, which is the company’s first mesenchymal stem cell (MSC) product for steroid-resistant acute graft-versus-host disease (GvHD). This is another milestone and value catalyst for the stem cell company in the journey to determine the safety and effectiveness of CYP-001 for the devastating disease. Moreover, a total of 8 patients are expected to participate in Cohort B, and this when combined with the 8 patients already treated in Cohort A, makes a total of 16 patients in the phase 1 trial. The commencement of the second patient cohort (Cohort B) signifies the advancement towards completion of the trial, which is expected later in 2018. Additionally, CYP has signed the MoU with Celularity, Inc. for the evaluation and identification of commercial opportunities for the Cymerus platform and Celularity’s leading cell therapy assets. As a result, CYP stock has risen 21.67% in one month as on January 24, 2018 and soared 13.7% on January 25, 2018. We give a “Hold” recommendation on the stock at the current price of $0.83
 

Aumake International Ltd

Completed the fund raising: Up 175% in last three months as at January 24, 2018, Aumake International Ltd (ASX: AU8) has raised $14 million (before capital raising costs) through the placement of 31,111,120 fully paid ordinary shares at an issue price of 45 cents per share. Moreover, AU8 will use the funds to boost its retail store rollout program with a minimum of 20 retail stores in key locations across Australia including the development of Daigou Hubs in China and Australia. Further, the company will increase its investment in and production of AuMake own branded products and also increase the investment in the development and growth of loyal WeChat online members, which is currently 13,000. The company is exploring and executing the acquisition opportunities where appropriate (including milk formula). On the other hand, AU8 stock has fallen 33.83% in one month as on January 24, 2018 despite a decent trading update for December 2017 with indicative growth across all financial indicators with significant gross profit margin growth to at least 15.8% resulting in a MoM increase of 20% or greater from November 2017 (13.1%). While we look for more key catalysts for growth, we believe that the stock is “Expensive” at the current price of $0.41

Disclaimer
 
The advice given by Kalkine Pty Ltd and provided on this website is general information only and it does not take into account your investment objectives, financial situation or needs. You should therefore consider whether the advice is appropriate to your investment objectives, financial situation and needs before acting upon it. You should seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice. Not all investments are appropriate for all people. Kalkine.com.au and associated pages are published by Kalkine Pty Ltd ABN 34 154 808 312 (Australian Financial Services License Number 425376). The information on this website has been prepared from a wide variety of sources, which Kalkine Pty Ltd, to the best of its knowledge and belief, considers accurate. You should make your own enquiries about any investments and we strongly suggest you seek advice before acting upon any recommendation. Kalkine Pty Ltd has made every effort to ensure the reliability of information contained in its newsletters and websites. All information represents our views at the date of publication and may change without notice. To the extent permitted by law, Kalkine Pty Ltd excludes all liability for any loss or damage arising from the use of this website and any information published (including any indirect or consequential loss, any data loss or data corruption). If the law prohibits this exclusion, Kalkine Pty Ltd hereby limits its liability, to the extent permitted by law to the resupply of services. There may be a product disclosure statement or other offer document for the securities and financial products we write about in Kalkine Reports. You should obtain a copy of the product disclosure statement or offer document before making any decision about whether to acquire the security or product. The link to our Terms & Conditions has been provided please go through them and also have a read of the Financial Services Guide. On the date of publishing this report (mentioned on the website), employees and/or associates of Kalkine Pty Ltd do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations.